Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Neuroblastoma (Pediatrics)

A Randomized Clinical Trial Comparing ctDNA-directed Therapy Change with Standard of Care in Patients with Metastatic Triple Negative Breast Cancer

Breast

A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly Diagnosed Acute Lymphoblastic Leukemia with Randomization of KMT2A Rearranged Patients to Addition of Venetoclax

DENALI-1: A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod(TM) CAR T, in Heterozygous HLA-A*02 Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression.

Miscellaneous

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors

Multiple Cancer Types

An International, Prospective, Open-Label, Multi-Center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients with Prostate-Specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)

Prophylactic Reinforcement of Ventral Abdominal Incisions Trial (PREVENT): Prospective, Multi-Center, Open-Label, Randomized, Controlled Trial of Phasix Mesh to Prevent Incisional Hernia Subsequent to Open Midline Laparotomy.

Miscellaneous

A Randomized, Open-Label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BRAF Wild-Type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Multiple Cancer Types

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors

Multiple Cancer Types

Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors.

Lung